A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Neovascularization is crucial for brain tumor growth, invasion, and metastasis.
• Vascular Endothelial Growth Factor (VEGF) signaling inhibitors have shown limited efficacy due to alternative angiogenic pathways.
• Tumors utilize compensatory growth factor pathways to sustain angiogenesis.

Purpose of the Study:

• To review recent literature on multi-kinase inhibitors for brain tumors.
• To evaluate the preclinical and clinical effects of these inhibitors.
• To highlight the potential of multi-target therapies in overcoming resistance.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of multi-kinase inhibitors targeting angiogenic growth factor receptors (VEGFR, PDGFR, FGFR, etc.).
• Focus on FDA-approved inhibitors since 2009.

Main Results:

• Multi-kinase inhibitors demonstrate potential in obstructing various angiogenic pathways simultaneously.
• These inhibitors offer a more holistic approach compared to single-target therapies.
• Recent data show promising preclinical and clinical effects on brain tumors.

Conclusions:

• Multi-kinase inhibitors represent a significant advancement in brain cancer treatment.
• Targeting multiple angiogenic pathways is a more effective strategy than single-target inhibition.
• Further research and clinical application of these inhibitors are warranted.